JP7605747B2 - 修飾されたｇｉｐペプチド類似体 - Google Patents

修飾されたｇｉｐペプチド類似体 Download PDF

Info

Publication number
JP7605747B2
JP7605747B2 JP2021552785A JP2021552785A JP7605747B2 JP 7605747 B2 JP7605747 B2 JP 7605747B2 JP 2021552785 A JP2021552785 A JP 2021552785A JP 2021552785 A JP2021552785 A JP 2021552785A JP 7605747 B2 JP7605747 B2 JP 7605747B2
Authority
JP
Japan
Prior art keywords
gip
seq
amino acid
peptide
functional variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552785A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020115048A5 (enExample
JP2022509568A (ja
Inventor
スパール‐ウリッチ，アレクサンダー，ホヴァード
シヴァースン，ビアン，ビエンズ
リバー，ディッテ
ロースンキーレ，メッテ，マリー
Original Assignee
アンタグ セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンタグ セラピューティクス エーピーエス filed Critical アンタグ セラピューティクス エーピーエス
Publication of JP2022509568A publication Critical patent/JP2022509568A/ja
Publication of JPWO2020115048A5 publication Critical patent/JPWO2020115048A5/ja
Application granted granted Critical
Publication of JP7605747B2 publication Critical patent/JP7605747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021552785A 2018-12-03 2019-12-03 修飾されたｇｉｐペプチド類似体 Active JP7605747B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18209896.2 2018-12-03
EP18209896 2018-12-03
EP19176739 2019-05-27
EP19176739.1 2019-05-27
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues

Publications (3)

Publication Number Publication Date
JP2022509568A JP2022509568A (ja) 2022-01-20
JPWO2020115048A5 JPWO2020115048A5 (enExample) 2022-12-07
JP7605747B2 true JP7605747B2 (ja) 2024-12-24

Family

ID=68731999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552785A Active JP7605747B2 (ja) 2018-12-03 2019-12-03 修飾されたｇｉｐペプチド類似体

Country Status (11)

Country Link
US (3) US12187773B2 (enExample)
EP (2) EP3891173A1 (enExample)
JP (1) JP7605747B2 (enExample)
CN (1) CN113366014B (enExample)
AU (2) AU2019391300B2 (enExample)
BR (1) BR112021010447A2 (enExample)
CA (1) CA3121043A1 (enExample)
IL (1) IL283385A (enExample)
MX (1) MX2021006505A (enExample)
SG (1) SG11202105586YA (enExample)
WO (2) WO2020115049A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250346647A2 (en) * 2019-12-03 2025-11-13 Antag Therapeutics Aps Optimized GIP Peptide Analogues
CN116133677A (zh) * 2020-07-06 2023-05-16 鸿绪生物医药科技（北京）有限公司 新型多肽制剂及其治疗用途
EP4177263A4 (en) * 2020-07-06 2024-11-13 Vitalixir (Beijing) Co., Ltd NEW POLYPEPTIDE AND ITS THERAPEUTIC USE
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
JP2024521398A (ja) * 2021-06-10 2024-05-31 アンタグ セラピューティクス エーピーエス 肥満及び肥満関連障害の治療
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
CR20250051A (es) * 2022-07-13 2025-03-18 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista dual de glp-1/gip, método de preparación y uso del mismo
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
WO2024209050A1 (en) * 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5745335A (en) 1996-06-27 1998-04-28 Gennum Corporation Multi-layer film capacitor structures and method
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
DE69900026T2 (de) 1998-01-30 2001-05-10 Novo Nordisk As Eine injektionsspritze
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
JP2002526554A (ja) 1998-10-07 2002-08-20 メディカル カレッジ オブ ジョージア リサーチ インスティチュート，インコーポレイテッド 骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
ATE272650T1 (de) 1999-03-29 2004-08-15 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
DE60216629T2 (de) 2001-09-21 2007-10-11 Koninklijke Philips Electronics N.V. Gibt es kein spezifisches kontrollmodul? benutzen sie eines das weniger spezifisch ist
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
EP2987805A3 (en) 2008-08-07 2016-04-13 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
KR20110043688A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
PT2320923E (pt) 2008-08-07 2015-02-24 Ipsen Pharma Sas Análogos truncados de polipéptido insulinotrópico dependente de glucose
EA020091B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
EP2718317B1 (en) * 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
US9340600B2 (en) * 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
US10774127B2 (en) 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
CN110312532A (zh) * 2016-12-19 2019-10-08 韩美药品株式会社 脑靶向长效蛋白质缀合物
US11319369B2 (en) 2016-12-26 2022-05-03 Kao Corporation Motor control function improving agent
JP7165496B2 (ja) 2016-12-26 2022-11-04 花王株式会社 認知機能改善剤
US20190330332A1 (en) 2016-12-26 2019-10-31 Kao Corporation Hypothermia Ameliorating Agent
KR102743887B1 (ko) 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Diabetologia，2015年，Vol.58，p.2144-2153
J.Med. Chem.，2006年，Vol.49，p.1047-1054
Molecular and Cellular Endocrinology，2015年，Vol.401，p.120-129

Also Published As

Publication number Publication date
US12297250B2 (en) 2025-05-13
US20220025010A1 (en) 2022-01-27
MX2021006505A (es) 2021-10-01
BR112021010447A2 (pt) 2021-08-24
CN113366014B (zh) 2025-10-21
WO2020115049A1 (en) 2020-06-11
US20250376499A1 (en) 2025-12-11
CA3121043A1 (en) 2020-06-11
CN113366014A (zh) 2021-09-07
SG11202105586YA (en) 2021-06-29
IL283385A (en) 2021-07-29
AU2019391300A1 (en) 2021-07-01
AU2025237957A1 (en) 2025-10-16
EP3891174A1 (en) 2021-10-13
AU2019391300B2 (en) 2025-06-26
EP3891173A1 (en) 2021-10-13
US12187773B2 (en) 2025-01-07
KR20210102911A (ko) 2021-08-20
JP2022509568A (ja) 2022-01-20
US20220298218A1 (en) 2022-09-22
WO2020115048A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
JP7605747B2 (ja) 修飾されたｇｉｐペプチド類似体
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
CN108135981A (zh) 胰高血糖素受体激动剂
CN114787183A (zh) 肠促胰岛素类似物及其用途
CN110691788B (zh) 长效gip肽类似物
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
KR102906485B1 (ko) 변형된 gip 펩티드 유사체
CA3064510C (en) Long-acting gip peptide analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241212

R150 Certificate of patent or registration of utility model

Ref document number: 7605747

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150